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Chronic Myeloid Leukemia With Permanent
Disappearance of the Ph’ Chromosome and
Development of New Clonal Subpopulations
By A. Hagemeijer, E. M. E. Smit, B. L#{246}wenberg, and J. Abels
A 6.5.yr follow-up study is reported on a
case of chronic myeloid leukemia (CML)
diagnosed in 1971 in a man of age of 19
yr. At that time the Ph1 chromosome was
found in all of his bone marrow cells. After
4 yr of intermittent treatment his blood
and bone marrow still showed a florid CML
picture, but the karyotypes of bone mar-
row, blood, and spleen cells were normal.
Blastic transformation occurred after 5.5
yr and was accompanied by a hyperdiploid
karyotype (49,XY,+9,+1O,+12) without
reappearance of the Ph1 chromosome.
After successful chemotherapy the karyo-
type again became normal. In 1977 cells
with a new clonal aberration (l4p+)
gradually became the dominating bone
marrow cell population, while the periph-
eral blood was compatible with CML.
The 14p+ clone subsequently decreased
at the expense of the 49,XY,+9,+ 10,+ 12
clone, which had reappeared in the ma-
jority of the dividing blood cells. Also,
a new clonal subpopulation 45,XY,t(5p;
1 7q) was found in 7% of the metaphases.
This coincided with the occurrence of a
second blast transformation, which was
treated with chemotherapy. The karyo-
types of all dividing cells during the re-
covery from the induced severe bone mar-
row hypoplasia still showed the t( 5p; 1 7q)
abnormality and chromosome numbers
varying from 45 to 51. In some cells ad-
ditional trisomies were seen as an indica-
tion of a clonal evolution. One month be-
fore the patient’s death a fourth abnormal
cell line was seen in 10% of the dividing
blood cells.
T HE PHILADELPHIA CHROMOSOME (Ph’), described by Nowell and
Hungerford in 1960,’ is a specific acquired anomaly in the bone marrow
(BM) karyotype of almost 90#{176}cof patients with chronic myeloid leukemia
(CML). Banding techniques have identified the Ph’ anomaly as a translocation
of the larger part of the long arm of chromosome 22 onto another chromo-
some, usually the long arm of chromosome 9: t(9q+,22q-).2
Recent reviews of CML patients have stressed the correlation between
karyotype and prognosis:3 6
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UNUSUAL CYTOGENETIC EVOLUTION IN CML 3
(I) Ph’-negative CML patients have a poorer prognosis as compared with
Ph’-positive patients, i.e., shorter survival, poorer response to therapy, and
earlier acceleration ofthe disease.4 (2) The natural history of PhLpositive CML
is such that after a chronic phase of 2-4 yr drug resistance, myelofibrosis, or
(in 80” of cases) an acute leukemia occurs. Additional chromosomal aberra-
tions in the Ph’-positive BM cells usually herald the development of acute
leukemia. (3) Very rare cases in which only a minority of the cells are Ph’-posi-
tive (either on the basis of mosaicism at diagnosis or as a therapeutically in-
duced cytogenetic conversion) have shown long remission and survival for up
to 17 yr.5 2
The present paper describes a case of CML in a young adult. His BM cells
were Ph’-positive at diagnosis, but complete conversion to PhLnegative cells
occurred during the chronic phase of the disease. A first blast crisis was marked
by an abnormal karyotype, but the Pht chromosome did not reappear. The pa-
tient responded well to chemotherapy, but after a temporary erythroid hyper-
plasia another blast transformation developed. These difI’erent clinical appear-
ances coincided with specific karyotypic changes.
CASE REPORT
The patient was a male born jn January 1952. Chronic mycloid leukemia was diagnosed in 1971
(age 19 yr) when the patient presented with general complaints. splenomegaly. typical blood and
bone marrow findings, and the presence of a Ph’ chromosome in his bone marrow cells. During
almost 5.5 yr. from June 1971 until December 1976, he was maintained in a variable clinical re-
mission ofhis disease with different therapeutic regimens: June and July 1971 and March through
May 1972, busulfan; November 1972, spleen irradiation: March and April 1973. dibromoman-
nitol; September 1973 through October 1975, hydroxyurea: November 1975. splenectomy: No-
vember 1975 through May 1976, hydroxyurea: May through December 1976. busulfan.
In December 1976 a blastic phase developed and was treated with doxoruhicin, vincristine,
and cytosine arabinoside according to a protocol of the European Organiiation for Research
on Treatment of Cancer (EORTC). An identical course was given in February 1977, and sub-
sequently a consolidation treatment with doxorubicin and cytosine arabinoside was given in
April 1977. The disease remitted again to a chronic phase, during which the patient was again
treated with hydroxyurea for 3 mo followed by busulfan for 5 mo. A second blast phase in De-
cember 1977 was treated with cytosine arabinoside, thioguanine, and daunomycin. This resulted
in a prolonged pancytopenia due to bone marrow depression. Fever, infections, intestinal bleeding,
and cachexy followed. In April 1978 an abdominal tumor was found to be causing intestinal
obstruction, and the patient died later that month. Pathologic examination showed generalized
infiltration of leukemic cells in lymph nodes, bone marrow, liver, lungs, kidneys, and the small
and large intestines. The mesenteric lymph nodes were particularly enlarged, forming a tumor of
lOx lOx 5cm and a paraaortic tumor of l0xfix5cm. A summary of the hematologic findings
during the different episodes is given in Table I.
From 1971 through 1976 the WBC counts remained rather elevated and blood and BM mor-
phology were consistent with a chronic phase of CML. During these years no episode of BM
hypoplasia was observed. Blast crisis was defined as the presence of at least 20”,, blasts and pro-
myelocytes in peripheral blood and 25”,, blasts in bone marrow. Frequent controls carried out since
December 1976 sequentially showed the therapeutically induced hypoplastic phase, the return
to a chronic CML with an erythroid overshoot, and the second blast crisis followed by hypoplasia.
Leukocyte alkaline phosphatase (LAP) values were repeatedly low or absent. Terminal deoxynu-
cleotidyl transferase tested in December 1977 gave the low value of 0.5 U/bt cells (as de-
termined in the laboratory of Dr. D. Catovsky. Royal Postgraduate Medical School, London),
which is consistent with a myeloid type of transformation.
Table 2. Results of Serial Chromosome Analyses and Colony Growth Assays
CFU-C
Clinical No. of Mitoses (per 1O5
Date Phase Tissue’ Analyzedt Koryotype Nucleated Cells)
6/1/71 Diagnosis BM
11/3/75 Chronic BM
Blood
Spleen
12/15/76 Blastic BM
12/22/76 Blood
0
9
ND
16
9
9
1 4
ND
ND
44gb
ND
*The blood cultures are unstimulated (no PHA).
tlotal number of mitoses analyzed and their repartition according to the observed karyotype.
Cytogenetic analysis of 21 colony cells was performed on day 14 of the culture with the follow-
ing results: 46,XY (2 cells); 49,XY,+9,+ 10,+ 12 (5 cells); and 45,XY,t(5p;17q) (14 cells).
§25% of the cells showed random breakage of chromosomes.
I Cytogenetic analysis of only four colony cells was possible and showed in all four karyotypes
44,XY,+8,t(1 lql2q),17p+,- 18,-22.
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MATERIALS AND METHODS
Routinely, BM was aspirated from the patient’s posterior superior iliac crest.
Morphology was examined on crush smears stained with May-GrUnwald-Giemsa, the PAS
technique, and Sudan black. LAP was scored according to the method of Kaplow.’3
Chromosome analyses were done on BM cells immediately suspended in Ham’s F10 medium
containing colchicine (0.25 g/ml). Short cultures of BM were also performed in partly condi-
tioned medium made of 3 vol fresh Ham’s FlO medium supplemented with l5” fetal calf serum
and 2 vol similar medium conditioned on a fibroblast culture. Whole blood was cultured for 24
50
27
6
31
ND
122
23
1/17/77 Hypoplastic BM 6 {
1/31/77 Remission BM 26 {TI
5/16/77 Chronic BM 27
Blood 6
8/16/77 Chronic BM 34 {
11/12/77 Blastic BM 32 26
Is
1
Blood 2216
12
12/19/77 Blostic Blood 40 i{34
13
(8
2/8/78 Hypoplastic Bloods 23 3
2/27/78 Recovery BM 45 {
3/13/78 Chronic Blood 45
3/23/78 Chronic Blood 35 ‘ 30
12
46,XY,Gq -
46,XY
,xv
46,XY
ND
49,XY,+9,+ 10,+ 12
46,xY
46,xY
49,xy,+9,+10,t12
46,xY
49,XY,+9,+ 1O,t 12
46,xY
46,XY
46,xY
46,XY, 14p+
46,XY
46,xY,14+
49,XY,+9,+ 10,+ 12
46,xY
46,XY,1 4p+
49,xY,+9,+ 10,+ 12
46,XY,14p+
49,XY,+9,+ 10,+ 12
45,XY,t(5p;1 7q)
46,XY
45,XY,t(5p; 1 7q)
49-’51 (Table 3)
45,xY,t(5p;1 7q)
46-51 (Table 3)
49 (Table 3)
44,XY,+8,t(11;12),17p+,- 18,-22
45,XY,t(5p;1 7q)
49 (Table 3)
44,XY,+8,t(1 1 ;l2),l7p+,- 18,-22
ND
59
ND
0
3
ND
0
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Fig. 1. Karyotype of first BM culture, 1971. Deleted G-group chromosome (Gq- or Ph’ chro-
mosome) was found in all metaphases. Standard Giemsa staining.
and 48 hr without phytohemagglutinin (PHA). A 48- or 72-hr lymphocyte culture (peripheral
blood, stimulated with PHA) was used as control.
In all cultures except those prepared in 1971, the chromosomes were identified with different
banding techniques: GAG (G bands by acetic saline using Giemsa), QFA (Q bands by fluorescence
using quinacrine), and RFA (R bands by fluorescence using acridine orange) according to the
nomenclature of the Paris Conference (1971) Supplement (l975).’ Silver staining of the
nucleolus organizer regions (NOR banding) was attempted according to the method of Tantravahi
et al.15
Colony assays for myeboid precursor cells in BM and blood were performed according to the
technique of Pike and Robinson.’6 Colonies of more than 100 cells were scored. Values for normal
marrow were 8-15 colonies/105 nucleated cells. Cells giving rise to colonies in vitro were
designated CFU-C (colony-forming units culture).
RESU ITS
Karyotype analyses of BM and blood cells were performed at different times
during the 6yr following diagnosis (Table 2).
In 1971, at diagnosis, 50 BM cells were analyzed. All of them showed a de-
letion of one of the G-group chromosomes, which was assumed to be the Ph’
chromosome (Fig. I). No banding technique was operational at that time, and
therefore definite identification of the Gq- was not achieved. The Y chromo-
some appeared to be rather large, as confirmed by Q banding (Fig. 2), and the
1 2 3 4 5
NM
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Fig. 2. G-group chromosomes of two metaphases from
BM culture, 1975. Note absence of deleted chromosome.
0 banding with quinacrine.
other chromosomes were scored as normal. For obvious reasons a possible
9q+ could not be detected. Later attempts to band the old preparations did not
succeed.
In 1975, none of the 64 metaphases analyzed in BM, blood, and spleen
showed the Ph’ chromosome: only a normal karyotype was observed (Fig. 2).
Clinically, the patient presented with a picture ofCML during its chronic phase
(Table I).
In December 1976, during blastic transformation, 22 of the 23 cells analyzed
in the BM contained 49 chromosomes with trisomy of chromosomes 9, 10, and
Fig. 3. BM karyotype during blast transformation, 1976: 49,XY,+9,+1O,+12. R banding with
acridine orange.
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Fig. 4. Karyotype of abnormal clonal population discovered in August 1977: 46,XY,14p+.
R banding with acridine orange.
12 but no Ph’ (Fig. 3). Chemotherapy resulted in severe BM hypoplasia and
subsequent clinical remission accompanied by the disappearance of the ab-
normal clonal population (May 1977). In August 1977 a new clonal aberration
(14p+) appeared in 50#{176}cof the cells (Fig. 4). Definite identification of this
anomaly was not achieved. Combination of the banding techniques suggested a
translocation onto l4pl 1 of either the terminal part of chromosome 9q (band
9q33 - qter) or the terminal part of chromosome 4p (band 4p53 -k pter), but a
more complex rearrangement cannot be excluded. NOR banding showed
absence of silver staining on the 14p+. Concomitant with the development of
this new clone, an increase in myeloid blast cells and normoblasts in peripheral
blood was observed (Table I). A relapse of the blast crisis was foreshadowed
in November 1977, when 15#{176},,of the metaphases showed the reappearance of
the ancient clone with the 49,XY,+9,+ lO,+ 12 karyotype characteristic of the
first blast crisis. This clone became prominent in December (second blastic
phase) and disappeared after chemotherapy (February 1978).
In December 1977, 7.5#{176},,of the mitoses showed a new chromosomal aberra-
tion: 45,XY,-5,-l7,+mar. The new marker chromosome appeared as the
result of a translocation of the entire short arm of chromosome 5 (5p) onto the
entire long arm of chromosome 17 (l7q), abbreviated t(5p:l7q). The break-
HAGEMEIJER ET AL.
Fig. 5. Karyotype of subclone with 49 chromosomes, derived from the stem line with t( Sp;l 7q),
that became prominent in February and March 1978: 49,XY,-5,+6,+8,+9,- 17,+t(5p;17q),
t(18;21)(q21 ;pl 1),+ 19. Chromosome t(5p;17q) and der(18) and der(21) arrows. R banding with
acridine orange.
points were at or very near the centromeres. Both chromosome arms (5p and
l7q) were complete: whether the centromeres belong to chromosome 5 or 17 or
to both is unclear (Fig. 5).
During the period of BM hypoplasia following chemotherapy further clonal
evolution of this cell line was observed (Table 3). Analysis of the sequential
Table 3. Clonal Evolutio n of the Stem Line 45, XY,t(5; 17)
No. of
Chromosome Karyotypic Changes
No. of Cells Analyzed 05:
2/8/78’ 2/27/78t 3/13/78” 3/23/78’
45
46
49
49
49
50
51
t(5;17)
t(5;17) +8
t(5;l7)+6+8+9
t(5;17) +6+8+9
t(5;17)+6+8+9 l2p
t(5;17)+6+8+9 +12
t(5;17)+6+8+9+9+12
+19
+19t(l8;2l)
+19
+19
+19
3
0
4
2
0
1
3
12
1
10
13
4
4
1
0
0
15
21
5
0
0
3
0
1
29
0
0
0
“Unstimulated blood culture.
tUncultured BM cells.
tStands for -5,- 17,+t(5p;17q).
§Stands for t( 1 8;2 1 )(q2 1 ;pi 1).
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Fig. 6. Karyotype of clonal population discovered in March 1978:44,XY,+8,- 11,- 12,+t(11q;
12q),17p+,- 18,-22. 0 banding with quinacrine.
changes showed that the 49-chromosome subclone had evolved in three direc-
tions: + 12, l2p+, and t(l8;2l). The subclone with t(l8:2l) became the dom-
inant population in later analyses (Fig. 5). The translocation between chromo-
somes 18 and 21 was apparently balanced: t(l8;2I)(q21:pl I). As shown in Figs.
2 and 3 the chromosome 21 involved had only small satellites with dull fluores-
cence. Careful analysis of the karyotypes seemed to indicate that the proximal
part of 21p remained on the der(2I) on which the terminal part of I8q was
translocated. Satellites were never clearly seen on the long arm of der(l8).
In March 1978 still another karyotypic change was observed in four cells:
44,XY,+8,- 11,- l2,+t(l lql2q), l7p+,- 18,-22 (Fig. 6). The translocation
chromosome t(l lq:l2q) contained complete long arms of both chromosomes
involved (11 and 12), placing the breakpoints at or very near the centromeres.
C banding showed only one centromere. Studies of the l7p+ chromosome by
Q and R banding strongly suggested a translocation of a part of the long arm
of chromosome 22 onto l7p: exact breakpoints could not be determined. This
last clone, as well as the stem line with the t(5p;l7q), had two normal chromo-
somes 14 and no Ph’ chromosome, which indicates that these clones were also
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independently derived from a cell with a normal karyotype. Random breakage
of chromosomes was also found rather frequently in the four final analyses.
Lymphocyte cultures performed during and after chemotherapy showed
many more instances of random breakage and aneuploidy than the BM meta-
phases. In BM the high rate of cell division probably eliminated damaged
cells quite rapidly.
Colony assays for myeloid precursors showed the classical increase in num-
ber of colonies during CML and a decrease during blastic transformation.
During remission the number of colonies returned to normal. Surprisingly,
the number of colonies remained normal in the second blastic phase. Cyto-
genetic analysis ofthese colony cells showed that 14 of the 21 mitoses analyzed
carried the 45,XY,t(5p;17q) karyotype, an indication that the majority of the
myeloid precursors belonged to a particular subpopulation. A similar observa-
tion was made 3 mo later when the colony cells again belonged to the last de-
veloped clonal population with the t(l lq:12q).
DISCUSSION
Three different aspects make this clinical and cytogenetic observation remark-
able: first, the fact that complete conversion from Ph’+ CML into Ph’- CML
occurred in the interval 1971-1975 without an episode of BM aplasia and with-
out a clinical or hematologic remission of any significant length of time; second,
the favorable therapeutic response of the blast transformation leading to hema-
tologic, clinical, and cytogenetic remission; and third, the development in the
patient’s final 6 mo of different cytologic and clinical changes accompanied
by the proliferation in BM of new clonal subpopulations identified by chromo-
somal markers.
Ph’ conversion and CML diagnosis. In almost 90#{176}-aof CML, transforma-
tion of one stem cell’7 results in a Ph’+ clone that gradually overgrows pre-
existent hemopoiesis, leading to myeloid hyperplasia. Maturation of myeloid
cells occurs, and for 2--4 yr the disease can relatively easily be maintained thera-
peutically in a chronic stage. When blastic transformation ultimately follows, it
is in most cases heralded and accompanied by additional cytogenetic abnormal-
ities. Our patient characteristically fits the clinical patterns of Ph’+ CML if no
account is taken of the loss of the Ph’ chromosome.
Two additional categories of CML can be distinguished: (1) Ph’-CML has a
poor prognosis and a rapid evolution into an acute phase. Median survival is
only 8 mo, compared to 40 mo for Ph’+ CML.4 Our patient, who converted
to a Ph’- condition, did not fulfill the clinical criteria of this subgroup. (2)
In rare cases the transformed clone, marked by Ph’, does not dominate the
normal stem cell population and remains a minority. Five such cases of mosa-
icism have been reported,6- 12 characterized by long periods (6-10 yr) of therapeu-
tically induced complete remission and by long survival without the occurrence
of a blast crisis in the observation period. An episode of iatrogenic BM hypo-
plasia was reported in three of the five cases. The findings in our patient con-
trast with these observations in that no mosaicism was found in 1971, when all
mitotic BM cells were Ph’+, nor after 1975, when all cells were Ph1-; also,
no episode of bone marrow hypoplasia (nor a prolonged remission) was noted.
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During the blastic phase there was no return of a Ph’+ cell population and
the newly acquired cytogenetic abnormalities appeared in a Ph’- stem cell. In
May and June 1971 there was no other patient with CML for whom chromo-
some analysis was carried out. Therefore we feel confident that laboratory
mistakes are excluded and that at that time our patient had the Ph’ chromo-
some in most ifnot all ofhis BM cells.
All attempts to explain cytogenetic and clinical findings of this case must be
more or less hypothetical because of the lack of cytogenetic observations be-
tween 1971 and 1975. One explanation could be that a Ph’+ CML was cured
with eradication of the Ph’+ clone and that this patient later developed an
acute myeloid leukemia. Another explanation could be that the Ph’+ clone
regressed with concomitant reappearance of normal stem cells (Ph’-) in the
hematopoietic tissues; subsequently a new transformation of one or more stem
cells may have resulted in a Ph’- CML cell line more virulent than the Ph’ +
one and overgrowing it. The fact that the new cytogenetically abnormal sub-
populations that later emerged stemmed from a Ph’- cell also supports the no-
tion of two successive transformations on different stem cells. In favor of the
AML hypothesis are the absence of a Ph’ chromosome and the complete remis-
sion obtained by chemotherapy accompanied by the return of a normal karyo-
type. Nevertheless, we did not retain this interpretation on clinical grounds: from
diagnosis (1971) until the first blastic phase there was no remission in the patient’s
disease; hyperactive myelopoiesis was always present as evidenced by the total
and differential blood counts. In 1975 the clinical picture was that of a florid
CML, splenomegaly had become resistant to drug therapy and a splenectomy was
performed, the LPA was low, and cytogenetic analysis showed only cells with a
normal karyotype, suggesting a Ph’- CML. Furthermore, both times when re-
mission of blast crisis was achieved the hematologic picture returned to a CML
pattern in chronic phase, and the postmortem pathologic analysis of the lymph
nodes did not show a monotonous blast infiltration but a variegated myeloid
picture with different stages of maturation of the cells.
Blastic transformation. The cytogenetic abnormalities that developed during
the blastic phase did not help in discriminating between AML and Ph’- CML
blast crisis. In both diagnoses, trisomy of C-group chromosomes, regression of
the abnormal clone during remission, appearance of new clones, and clonal
evolution have been described.’8 2l Trisomy 8 is the most common trisomy C
reported in AML as well as in CML blast crisis.’8 21 Here the hyperdiploid
karyotype showed trisomies of chromosomes 9, 10, and 12, which have also
been described individually in both diagnoses’8’2224 but not in this particular as-
sociation. In this observation trisomy 8 was found in clones that appeared later
in the evolution of the disease (Figs. 5 and 6).
Twice, 1 yr apart, the patient developed a blast crisis accompanied by the
rapid increase in BM of the same abnormal clone with the 49,XY,+9,+ lO,+ 12
karyotype. Both times this subpopulation responded to chemotherapy and dis-
appeared from the proliferating pool at the benefit of cells with a normal
karyotype and, the second time only, cells derived from another clone with the
t(5p;l7q). This is one of the few cases of documented cytogenetic remission of
CML in blast crisis.
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t
JUN NOV DEC MAY AUG. NOV DEC FEB. MAR. APR
1971 1975 1976 1977 1977 1977 1977 1978 1978 1978
::   46.xy, lAp’
 46.xy. Ph1 t:::  -s. -17, .t(Spllq)
- 49,xy..9..10..12 NOT observed.Presumably present
In a non-proliferative stage
11110111111144.xy..8.t(llql2q).t(17,22).-18
c-:-:-:49.xy.t(5p17q).-6..8..9..19.t(18.21)
Fig. 7. Schematic representation of different clonal populations found in BM mitotic cells of
our patient from June 1971 to March 1978.
Development of new clonal populations. Figure 7 represents a scheme of the
appearance and development of karyotypically different subpopulations as they
were observed in our patient between June 1971 and March 1978. At least five
times a new clone appeared, apparently stemming from a cell with a normal
karyotype. This is at variance with the usual pattern in CML, where stepwise
changes are observed in a Ph’+ stem cell, similar to what we found in our last
cytogenetic analysis of this patient (Table 3).
Cytogenetic analysis gives information on the population of cells undergoing
mitosis in vivo or in short culture, so that only a limited number of cells can be
analyzed. Therefore a subpopulation of cells that is poorly represented or is in a
non proliferative stage may escape detection. This explains why, although at one
particular time we failed to find cells with a normal karyotype, these cells may
later, after chemotherapy, represent the majority of the proliferative pool.
Similarly, this explains why the “blastic” karyotype with 49 chromosomes, ap-
parently eliminated from BM in May 1977, could reappear in November 1977
together with a relapse of the blast crisis.
It is not likely that the hyperdiploid clones with trisomy of chromosomes of
the C group or trisomy 17, 19, etc. are therapeutically induced, since they have
been seen in AL and in blast crisis of CML in untreated patients and in patients
treated with widely different approaches. In cases of random structural aberra-
tions, like our i4p+, the role played by therapy in the initiation of th abnor-
mal clone is difficult to evaluate. In any case, the abnormality must have started
in a stem cell still capable of proliferation and furthermore gaining prolifera-
tive advantage over the other stem cells.
The 14p+ clone arose in August 1977 and became prominent in November,
but in December relapse of the blast crisis rapidly invaded the BM with cells
belonging to the 49,XY,+9,+ l0,+ 12 karyotype, and the l4p+ clone appears
to have been transient.
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The hypodiploid clone with the characteristic t(5p; 17q) presents a few inter-
esting features. It was observed for the first time during the second blast crisis,
when most of the mitotic cells belonged to the “blastic” clone with 49 chromo-
somes. At the same time, we did not observe the decrease in CFU-C seen during
the previous blast crisis. Karyotyping of the colony cells showed mainly mitoses
belonging to this new minor clone. Unfortunately, because morphology of the
colonies was not studied, the maturation capabilities of these cells in vitro, and
presumably in vivo, were not ascertained. Events during induction of remission
cannot be satisfactorily monitored because many cells are damaged. Neverthe-
less, during the hypoplastic phase we found in blood culture of our patient two
groups of metaphases-cells with a normal karyotype and cells with t(5p;l7q).
A few weeks later, most of the BM and blood metaphases showed a hyper-
diploid karyotype derived from this particular stem line (Table 3). This suggests
that this clone was not only relatively more resistant to chemotherapy than the
other, which disappeared, but also that it had the property of rapidly acquiring
new chromosomes by nondisjunction.
The fifth cell line, discovered 1 mo before the patient’s death, appeared less
malignant than the hyperdiploid cells proliferating at that time. The deteriora-
tion of the patient’s health was not caused by blastic transformation but by
generalization of the disease.
Close cytogenetic follow-up of this CML case turned out to be particularly
instructive. Apart from the Ph’ conversion and the favorable response to
chemotherapy of two blast crises, this case represents also, to the best of our
knowledge, the first observation of a transient clone (the l4p+) that developed
independently of blast transformation and receded not under chemotherapy but
because of the rapid takeover by a more malignant clonal population. Later,
the extensive clonal evolution stemming from the t(5p;17q) population indi-
cated a loss of mitotic control in this particular stem line and acceleration of
the leukemic process.
ACKNOWLEDGMENT
The authors thank Professor D. Bootsma (Department of Cell Biology and Genetics, Erasmus
University) for advice and support and thank Dr. F. A. Th. Lustermans and Dr. W. F. Stenfert-
Kroese, who treated this patient from 1971 to 1973.
REFERENCES
1. Nowell PC, Hungerford DA: A minute
chromosome in human chronic granulocytic
leukemia. Science 132:1497, 1960
2. Rowley JD: A new consistent chromo-
somal abnormality in chronic myelogenous leu-
kaemia identified by quinacrine fluorescence
and Giemsa staining. Nature 243:290-293, 1973
3. Whang-Peng J, Canellos GP, Carbone PP,
Tjio JH: Clinical implication of cytogenetic
variants in chronic myeloid leukemia (CML).
Blood 32:755-766, 1968
4. Edzinli EZ, Sokal JE, Crosswhite L, Sand-
berg AA: Philadelphia chromosome-positive
and -negative chronic myelocytic leukemia. Ann
Intern Med 72:175-182, 1970
5. Sakurai M, Hayata I, Sandbcrg AA: Prog-
nostic value of chromosomal findings in Ph’-
positive chronic myelocytic leukemia, Cancer
Res 36:313-318, 1976
6. Tough IM, Jacobs PA, Court Brown WM,
Baikie AG, Williamson ERD: Cytogenetic
studies on bone-marrow in chronic myeloid leu-
kaemia. Lancet 1:844-846, 1963
7. Finney R, McDonald GA, Baikie AG,
Douglas AS: Chronic granulocytic leukaemia
with Ph’ negative cells in bone marrow and a
14 HAGEMEIJER ET AL.
ten year remission afterbusulphan hypoplasia.
Br J Haematol 23:283-288, 1972
8. Maurice PA, Alberto P, Ferrier S, Freund
M: Leuc#{233}mie my#{233}locytaire chronique: G flerison
apparente depuis plus de 9 ans consecutive a
une hypoplasie m#{233}dullaire th#{233}rapeutique.
Schweiz Med Wochenschr 101:1781-1782, 1971
9. Brandt L, Mitelman F, Panani A, Lenner
HC: Extremely long duration of chronic my-
eloid leukaemia with Ph’ negative and Ph’ posi-
tive bone marrow cells. Scand J Haematol 16:
321-325, 1976
10. Golde DW, Bersch NL, Sparkes RS:
Chromosomal mosaicism associated with pro-
longed remission in chronic myelogenous leu-
kemia Cancer 37:1849-1852, 1976
II. Dowling MD, Hopfan S, Knapper WH,
Vaartaja T, Gee 1, Haghbin M, Clarkson BD:
Attempt to induce true remission in chronic
myelogenous leukemia (CML). Proc Am Assoc
Cancer Res 15:189, 1974 (Abstr)
12. Smalley RV, Vogel J, Huguley CM Jr.
Miller D: Chronic granulocytic leukemia: Cyto-
genetic conversion of the bone marrow with
cycle-specific chemotherapy, Blood 50:107-113,
1977
13. Kaplow LS: Histochemical method for
localizing and evaluating leukocyte alkaline
phosphatase activity in smears of blood and
marrow. Blood 10: 1023-1029, 1955
14. Paris Conference (1971), Supplement
(1975): Standardization in human cytogenetics.
Birth Defects: Original Article Series, XI, 9:5,
1975. The National Foundation, New York.
15. Tantravahi R, Miller DA, Miller OJ: Ag-
staining of nucleolus organizer regions of chro-
mosomes after Q-, C-, G- or R-banding proce-
dures. Cytogenet Cell Genet 18:363-369, 1977
16. Pike BL, Robinson WA: Human bone
marrow colony growth in agar gel. J Cell
Physiol 76:77-84, 1970
17. Fialkow PJ: The origin and development
of human tumors studied with cell markers.
N EngI J Med 29 1:26-35, 1974
18. Rowley JD: Non random chromosomal
abnormalities in hematological disorders of
man. Proc NatI Acad Sci USA 72:152-156, 1975
19. Hossfeld DK: Chronic myelocytic leu-
kemia: Cytogenetic findings and their relations
to pathogenesis and clinic. Ser Haematol
84:53-72, 1975
20. Lawler SD, O’Malley F, Lobb DS: Chro-
mosome banding studies in Philadelphia chro-
mosome positive myeloid leukaemia. Scand J
Haematol 17:17-28, 1976
21. Sharp JC, Potter AM, Keith Wood J:
Non-random and random chromosomal abnor-
malities in transformed chronic granulocytic
leukaemia. Scand J Haematol 16:5-12, 1976
22. Beck WS, Chesney I McC: Case records
of the Massachusetts General Hospital-Case
18-1973. N EngI J Med 288:957-963, 1973
23. Gahrton G, Lindsten J, Zech L: Involve-
ment of chromosomes 8, 9, 19 and 22 in Ph’
positive and Ph’ negative chronic myelocytic
leukemia in the chronic or blastic stage. Acta
Med Scand 196:355-360, 1974
24. Gall JA, Boggs DR, Chervenick PA, Pan
S. Fleming RB: Discordant pattern of chromo-
some changes and myeloblast proliferation dur-
ing the terminal phase of chronic myeloid leu-
kemia. Blood 47:347-353, 1976
